Resmed sees strong mask sales, strategic acquisitions and international expansion despite macro and competitive challenges.
IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner.
ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and significant cash reserves position it favorably for investors who want to protect their portfolio for a recession. RMD's operational efficiency and cash balance support continued dividend growth and potential buybacks.
| - Industry | - Sector | Michael J. Farrell BE, MBA, SM CEO | XBER Exchange | US7611521078 ISIN |
| US Country | 9,980 Employees | 13 Nov 2025 Last Dividend | 31 Aug 2010 Last Split | 2 Jun 1995 IPO Date |
ResMed Inc. is a pioneering company focused on developing, manufacturing, distributing, and marketing medical devices alongside cloud-based software applications tailored for the healthcare markets. With its operational base divided between Sleep and Respiratory Care, and Software as a Service (SaaS), ResMed is at the forefront of offering innovative solutions for managing respiratory disorders. The company's extensive product lineup and software solutions cater to both medical and consumer needs, aiming to improve patient outcomes through advanced technology and connectivity. Founded in 1989 and headquartered in San Diego, California, ResMed markets its products globally through a combination of direct sales forces and a network of distributors, targeting sleep clinics, home healthcare dealers, and hospitals.